Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Researchers have uncovered how mutations in a protein network drive several high-risk leukemias, offering new prospects for novel therapies.
Treatments for childhood cancer are often intense and carry the risk of lifelong health problems for survivors. An analysis of 23,600 childhood cancer survivors in the Childhood Cancer Survivor Study (CCSS), funded by the National Institutes of Health, found that the rate of severe health problems occurring five or more years after diagnosis has declined over time.
Many malignancies develop as a result of genetic alterations in individual cells. These gene mutations often cause altered proteins that give new, growth-promoting properties to the cell.
Many things go wrong in cells during the development of cancer. At the heart of the chaos are often genetic switches that control the production of new cells.
University of Georgia researchers, with colleagues from the University of Tokyo, have identified a new drug target for the two most common types of myeloid leukemia, including a way to turn back the most aggressive form of the disease.
UT Health San Antonio researchers discovered epigenetic changes that contribute to one-fifth of cases of acute myeloid leukemia (AML), an aggressive cancer that arises out of the blood-forming cells in bone marrow.
A targeted drug whose clinical testing was led by Richard Stone, MD, of Dana-Farber Cancer Institute, has become the first new treatment for newly diagnosed acute myeloid leukemia (AML) in more than 25 years.
Sarcomas- cancers of the connective tissues like muscles, joints, fat and bone -; come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers.
Some scientific reports have a profound impact on government policy. Sometimes, however, there are significant shortcomings in the research - yet the policy impact continues.
The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia who have a specific genetic mutation called FLT3, in combination with chemotherapy.
Second cancers in children and adolescents and young adults are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients ages 15-39 overall, a new study by UC Davis researchers has found.
Myelodysplastic syndrome is an umbrella term used to describe disorders characterized by the bone marrow's inability to produce normal blood cells.
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown that p300, a protein that increases gene expression by attaching acetyl molecules to DNA, may stop myelodysplastic syndrome (MDS) from developing into acute myeloid leukemia (AML). The study was published in the journal Leukemia.
The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models.
A large, new study of adults with acute myeloid leukemia (AML) correlates 80 cancer-related gene mutations with five subtypes of AML, which are defined by the presence of specific chromosomal abnormalities. The findings might help guide mutation testing and treatment decisions in the future.
Treatments for childhood cancers have improved to the point that 5-year survival rates are over 80 percent. However, one group has failed to benefit from these improvements, namely children who die so soon after diagnosis that they are not able to receive treatment, or who receive treatment so late in the course of their disease that it is destined to fail.
New findings from Rockefeller University researchers could guide the development of potent combination therapies that deliver more effective and durable treatment of leukemia.
A pair of drugs that may be a one-two punch needed to help combat acute myeloid leukemia (AML), an aggressive blood cancer that kills nearly three-fourths of patients within five years of diagnosis, is the focus of a new multi-center clinical trial that will enroll patients at three sites across the U.S.
Anyone who uses an employee badge to enter a building may understand how a protein called ENL opens new possibilities for treating acute myeloid leukemia (AML), a fast-growing cancer of bone marrow and blood cells and the second most common type of leukemia in children and adults.